公开(公告)号：EP1930433B1

公开(公告)日：2016-03-16

申请号：EP06797633.2

申请日：2006-09-07

申请人： Mie University ,  Takara Bio, Inc.

发明人： SHIKU, Hiroshi ,  HIASA, Atsunori ,  OKUMURA, Satoshi ,  NAOTA, Hiroaki ,  MIYAHARA, Yoshihiro

IPC分类号： C12N15/09 ,  A61K35/12 ,  A61K35/76 ,  A61K38/00 ,  A61K48/00 ,  A61P35/00 ,  C07K14/725 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10

CPC分类号： C07K14/705 ,  A61K35/12 ,  A61K38/00 ,  C07K14/7051 ,  C12N5/0636 ,  C12N2501/515 ,  C12N2510/00

公开(公告)号：EP1930433A1

公开(公告)日：2008-06-11

申请号：EP06797633.2

申请日：2006-09-07

申请人： Mie University ,  Takara Bio, Inc.

发明人： SHIKU, Hiroshi ,  HIASA, Atsunori ,  OKUMURA, Satoshi ,  NAOTA, Hiroaki ,  MIYAHARA, Yoshihiro

IPC分类号： C12N15/09 ,  A61K35/12 ,  A61K35/76 ,  A61K38/00 ,  A61K48/00 ,  A61P35/00 ,  C07K14/725 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10

CPC分类号： C07K14/705 ,  A61K35/12 ,  A61K38/00 ,  C07K14/7051 ,  C12N5/0636 ,  C12N2501/515 ,  C12N2510/00

摘要： A polypeptide comprising a polypeptide consisting of an amino acid sequence shown in SEQ ID NO: 5 of Sequence Listing or a polypeptide consisting of an amino acid sequence having deletion, addition, insertion or substitution of one to several amino acid residues in the sequence, the polypeptide being capable of constituting an HLA-A24-restricted, MAGE-A4 143-151 -specific T cell receptor together with a polypeptide consisting of an amino acid sequence shown in SEQ ID NO: 2 of Sequence Listing.

摘要翻译： 一种多肽，其包含由序列表的SEQ ID NO：5所示的氨基酸序列组成的多肽或由序列中一至数个氨基酸残基的缺失，添加，插入或取代的氨基酸序列组成的多肽， 能够构成HLA-A24限制性MAGE-A4 143-151特异性T细胞受体的多肽以及由序列表的SEQ ID NO：2所示的氨基酸序列组成的多肽。

公开(公告)号：EP3744845A1

公开(公告)日：2020-12-02

申请号：EP19743810.4

申请日：2019-01-17

申请人： Mie University

发明人： SHIKU, Hiroshi ,  MIYAHARA, Yoshihiro ,  FUJII, Keisuke ,  JO, Tatsuro ,  KISHI, Hiroyuki

IPC分类号： C12N15/12 ,  A61K35/17 ,  A61K35/76 ,  A61K48/00 ,  A61P31/14 ,  A61P35/02 ,  C07K14/725 ,  C12N5/10 ,  C12Q1/02

摘要： An object of the present invention is to provide a technique for preventing or treating HTLV-1-associated diseases, such as ATL, a material for use in the technique, a method for screening the material, and the like. The present invention provides a TCR screening method comprising sorting HTLV-1-derived antigen-recognizing cells from cells derived from an HTVL-1 patient and subjecting the HTLV-1-derived antigen-recognizing cells to TCR repertoire analysis, ranking the TCR types in descending order of the number of cells of each TCR type, and selecting a highly ranked TCR. The present invention provides a prophylactic or therapeutic agent for an HTLV-1-associated disease, the agent comprising a TCR comprising specific CDRs that can be obtained by the TCR screening method and cells expressing the TCR.

公开(公告)号：EP3636761A1

公开(公告)日：2020-04-15

申请号：EP18813904.2

申请日：2018-06-05

申请人： Mie University

发明人： SHIKU, Hiroshi ,  AKAHORI, Yasushi ,  KATO, Yuya ,  MIYAHARA, Yoshihiro

IPC分类号： C12N15/13 ,  A61K35/17 ,  A61P35/00 ,  C07K14/47 ,  C07K14/705 ,  C07K16/28 ,  C07K16/30 ,  C07K19/00 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/62 ,  C12N15/63 ,  C12N5/0783

摘要： [Problem] To provide CAR-T cells that can be used in CAR infusion therapy wherein a cancer-specific intracellular antigen is used.
[Solution] The problem is solved by CAR-T cells for cancer therapy provided with an antibody that recognizes the MAGE-A4-derived-peptide/HLA-A2 complex, wherein the antibody has VH amino acid sequence of SEQ ID NO: 36 and VL amino acid sequence of SEQ ID NO: 38. In the case, the antibody preferably is provided with the amino acid sequence of SEQ ID NO: 32.